aTYR PHARMA INC Finance Lease, Liability, Undiscounted Excess Amount
aTYR PHARMA INC (ATYR) had Finance Lease, Liability, Undiscounted Excess Amount of $176.00 thousand as of 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Notes › Leases
us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount · last filed 2024-11-07
- 2024-09-30: Finance Lease, Liability, Undiscounted Excess Amount $176.00K.
- 2024-06-30: Finance Lease, Liability, Undiscounted Excess Amount $210.00K.
- 2024-03-31: Finance Lease, Liability, Undiscounted Excess Amount $245.00K.
- 2023-12-31: Finance Lease, Liability, Undiscounted Excess Amount $283.00K.
| Period end | Finance Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2024-09-30 | $176.00K 10-Q · filed 2024-11-07 |
| 2024-06-30 | $210.00K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $245.00K 10-Q · filed 2024-05-02 |
| 2023-12-31 | $283.00K 10-K · filed 2024-03-14 |
| 2023-09-30 | $293.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $325.00K 10-Q · filed 2023-08-09 |
| 2023-03-31 | $349.00K 10-Q · filed 2023-05-09 |
| 2022-12-31 | $213.00K 10-K · filed 2023-03-14 |
| 2022-09-30 | $123.00K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $75.00K 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |